Primary Prophylaxis with hematopoietic colony stimulating factor: Insights from a canadian cost-effectiveness analysis

Scott A. Strassels; Michael Dickson; Leann B. Norris; Charles L. Bennett

doi:10.1093/jnci/djt198

Primary Prophylaxis with hematopoietic colony stimulating factor: Insights from a canadian cost-effectiveness analysis

Scott A. Strassels
, Michael Dickson
, Leann B. Norris
, Charles L. Bennett

Research output: Contribution to journal › Editorial

Original language	English
Pages (from-to)	1072-1073
Number of pages	2
Journal	Journal of the National Cancer Institute
Volume	105
Issue number	15
DOIs	https://doi.org/10.1093/jnci/djt198
State	Published - Aug 7 2013

Access to Document

10.1093/jnci/djt198

Cite this

@article{abbb8aeeb2c24126b58fcd6732b237c9,

title = "Primary Prophylaxis with hematopoietic colony stimulating factor: Insights from a canadian cost-effectiveness analysis",

author = "Strassels, \{Scott A.\} and Michael Dickson and Norris, \{Leann B.\} and Bennett, \{Charles L.\}",

note = "Funding Information: Funding was provided in part from the National Cancer Institute (1R01CA 102713-01 to CLB and 1R01CA165609-01A1 to LBN); the South Carolina Center of Economic Excellence Center for Medication Safety Initiative (to CLB); the American Cancer Society (IRG 11100-KA00 to CLB and LBN); the University of South Carolina Advanced Support Programs for Innovative Research Excellence (to LBN); and the Doris Levkoff Meddin Medication Safety Program (to CLB and LBN).",

year = "2013",

month = aug,

day = "7",

doi = "10.1093/jnci/djt198",

language = "English",

volume = "105",

pages = "1072--1073",

journal = "Journal of the National Cancer Institute",

issn = "0027-8874",

number = "15",

}

TY - JOUR

T1 - Primary Prophylaxis with hematopoietic colony stimulating factor

T2 - Insights from a canadian cost-effectiveness analysis

AU - Strassels, Scott A.

AU - Dickson, Michael

AU - Norris, Leann B.

AU - Bennett, Charles L.

N1 - Funding Information: Funding was provided in part from the National Cancer Institute (1R01CA 102713-01 to CLB and 1R01CA165609-01A1 to LBN); the South Carolina Center of Economic Excellence Center for Medication Safety Initiative (to CLB); the American Cancer Society (IRG 11100-KA00 to CLB and LBN); the University of South Carolina Advanced Support Programs for Innovative Research Excellence (to LBN); and the Doris Levkoff Meddin Medication Safety Program (to CLB and LBN).

PY - 2013/8/7

Y1 - 2013/8/7

UR - https://www.scopus.com/pages/publications/84881642485

U2 - 10.1093/jnci/djt198

DO - 10.1093/jnci/djt198

M3 - Editorial

C2 - 23873406

AN - SCOPUS:84881642485

SN - 0027-8874

VL - 105

SP - 1072

EP - 1073

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

IS - 15

ER -

Primary Prophylaxis with hematopoietic colony stimulating factor: Insights from a canadian cost-effectiveness analysis

Access to Document

Other files and links

Cite this